CN102292097B - 染料木黄酮的晶型 - Google Patents

染料木黄酮的晶型 Download PDF

Info

Publication number
CN102292097B
CN102292097B CN200980155203.5A CN200980155203A CN102292097B CN 102292097 B CN102292097 B CN 102292097B CN 200980155203 A CN200980155203 A CN 200980155203A CN 102292097 B CN102292097 B CN 102292097B
Authority
CN
China
Prior art keywords
genistein
crystalline
salt
sodium salt
salt dihydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980155203.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN102292097A (zh
Inventor
安德斯·贝肯斯塔姆
斯特凡·伦马克
迈克尔-罗宾·威特
基思·洛里默
史蒂芬·沃特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axcentua Pharmaceuticals AB
Original Assignee
Axcentua Pharmaceuticals AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axcentua Pharmaceuticals AB filed Critical Axcentua Pharmaceuticals AB
Priority to CN201510205311.6A priority Critical patent/CN104860913B/zh
Publication of CN102292097A publication Critical patent/CN102292097A/zh
Application granted granted Critical
Publication of CN102292097B publication Critical patent/CN102292097B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
CN200980155203.5A 2008-12-11 2009-12-11 染料木黄酮的晶型 Expired - Fee Related CN102292097B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510205311.6A CN104860913B (zh) 2008-12-11 2009-12-11 染料木黄酮的晶型

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12178708P 2008-12-11 2008-12-11
US12177808P 2008-12-11 2008-12-11
US61/121,778 2008-12-11
US61/121,787 2008-12-11
PCT/US2009/067664 WO2010068861A1 (en) 2008-12-11 2009-12-11 Crystalline forms of genistein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510205311.6A Division CN104860913B (zh) 2008-12-11 2009-12-11 染料木黄酮的晶型

Publications (2)

Publication Number Publication Date
CN102292097A CN102292097A (zh) 2011-12-21
CN102292097B true CN102292097B (zh) 2015-05-27

Family

ID=42243089

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200980155203.5A Expired - Fee Related CN102292097B (zh) 2008-12-11 2009-12-11 染料木黄酮的晶型
CN201510205311.6A Expired - Fee Related CN104860913B (zh) 2008-12-11 2009-12-11 染料木黄酮的晶型

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510205311.6A Expired - Fee Related CN104860913B (zh) 2008-12-11 2009-12-11 染料木黄酮的晶型

Country Status (11)

Country Link
US (2) US9012495B2 (enExample)
EP (1) EP2373326B1 (enExample)
JP (3) JP5898958B2 (enExample)
KR (2) KR20110106355A (enExample)
CN (2) CN102292097B (enExample)
AU (1) AU2009324489B2 (enExample)
BR (1) BRPI0923504A2 (enExample)
CA (1) CA2746652C (enExample)
IL (2) IL213473A (enExample)
WO (1) WO2010068861A1 (enExample)
ZA (1) ZA201105045B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110106355A (ko) 2008-12-11 2011-09-28 악센투아 파마슈투칼스 아베 제니스테인의 결정성 형태
US7863325B2 (en) 2008-12-11 2011-01-04 Axcentua Pharmaceuticals Ab Crystalline genistein sodium salt dihydrate
WO2011104667A1 (en) * 2010-02-25 2011-09-01 Anthem Biosciences Private Limited Basic aminoacid salts of polyphenols
CN102442990B (zh) * 2010-10-12 2015-03-11 上海睿智化学研究有限公司 一种金雀异黄素烟酰胺共晶、其晶体及其制备方法
CN102442989B (zh) * 2010-10-12 2015-04-08 上海睿智化学研究有限公司 一种金雀异黄素盐、其晶体及其制备方法
CN102442991B (zh) * 2010-10-12 2015-03-11 上海睿智化学研究有限公司 一种金雀异黄素维生素b6共晶、其晶体及其制备方法
CN105963246B (zh) * 2016-05-06 2018-12-25 荆楚理工学院 一种染料木素盐口服溶液剂及制备方法和应用
CN105853350A (zh) * 2016-05-24 2016-08-17 荆楚理工学院 一种染料木素溶液及制备方法和应用
CN109666014A (zh) * 2018-12-12 2019-04-23 荆门医药工业技术研究院 一种染料木素衍生物盐的制备方法及其应用
US20240058298A1 (en) 2020-12-03 2024-02-22 Delta 4 Gmbh Genistein for use in the treatment of focal segmental glomerulosclerosis (fsgs)
CN119095592A (zh) 2022-04-28 2024-12-06 绿石生物科学公司 大麻素的不良心血管作用的治疗
CN122374320A (zh) 2023-11-28 2026-07-10 绿石生物科学公司 染料木素磷酸酯衍生物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4841077A (en) * 1985-11-18 1989-06-20 Yamanouchi Pharmaceutical Co., Ltd. Isoflavone derivatives, and salts thereof, and cancerocidal and immunosuppressive agents containing the same
WO2002081491A2 (en) * 2001-04-09 2002-10-17 Instytut Farmaceutyczny New genistein derivatives and pharmaceutical preparations containing them

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07506822A (ja) 1992-05-19 1995-07-27 ノボゲン　リサーチ　ピーティーワイ　リミッテッド フィト−エストロゲン，類似体またはその代謝産物を含有する健康補助剤
DE4331233A1 (de) * 1993-09-15 1995-03-16 Basf Ag Verfahren zur Herstellung von Hydroxyoxaalkylmelaminen
US5569459A (en) * 1995-02-15 1996-10-29 Bio-Virus Research Incorporated Pharmaceutical compositions for the management of premenstrual syndrome and alleviation of menopausal disorders
US5554519A (en) 1995-08-07 1996-09-10 Fermalogic, Inc. Process of preparing genistein
PL179170B1 (pl) * 1995-09-15 2000-07-31 Inst Lekow Nowe zwiazki,pochodne genisteiny PL PL PL PL
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9613455D0 (en) * 1996-06-27 1996-08-28 Aston Molecules Ltd Analogues or derivatives of quercetin
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
US5981775A (en) 1998-09-16 1999-11-09 Board Of Trustees Operating Michigan State University Process for the preparation of isoflavones
US6194469B1 (en) * 1998-12-11 2001-02-27 Board Of Trustees Operating Michigan State Univeristy Method for inhibiting cyclooxygenase and inflammation using cherry bioflavonoids
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
AUPQ520300A0 (en) * 2000-01-21 2000-02-17 Novogen Research Pty Ltd Food product and process
BR0111230A (pt) 2000-05-31 2003-06-10 Astrazeneca Ab Composto, e, uso e processo para a preparação do mesmo
ATE265858T1 (de) * 2000-06-16 2004-05-15 Linnea Sa Wasserlöslicher komplex eines ginkgo biloba extrakts, verfahren zu dessen herstellung und diesen enthaltende zusammensetzung
KR20030014425A (ko) 2000-07-07 2003-02-17 앤지오젠 파마슈티칼스 리미티드 혈관 손상제인 콜치놀 유도체
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
US6541613B2 (en) * 2000-12-15 2003-04-01 Uyrex Corporation Isoflavone derivatives
CN100348592C (zh) * 2001-12-28 2007-11-14 中国人民解放军第二军医大学 3，7，8－三取代－5－羟基苯并－γ－吡喃酮类化合物及其制备方法
US20040023981A1 (en) * 2002-07-24 2004-02-05 Yu Ren Salt forms with tyrosine kinase activity
UA83814C2 (ru) 2002-12-24 2008-08-26 Астразенека Аб Производные фосфонооксихиназолина и их фармацевтическое применение
EP1765379A4 (en) * 2004-06-17 2009-05-27 Transform Pharmaceuticals Inc PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS AND RELEVANT USE METHOD
ATE473737T1 (de) * 2004-07-20 2010-07-15 Furfural Espanol S A Verwendung von 2,3-dehydronaringenin-derivaten zur behandlung von entzündungsprozessen und diese derivate enthaltende pharmazeutische zusammensetzung
ES2351257T3 (es) * 2005-02-15 2011-02-02 Dsm Ip Assets B.V. Composiciones que contienen polisacáridos.
ATE520396T1 (de) * 2005-06-29 2011-09-15 Dsm Ip Assets Bv Isoflavon-nanoteilchen und ihre verwendung
EP1921916A2 (en) * 2005-08-11 2008-05-21 The Scripps Research Institute Genistein inhibition of transthyretin amyloidosis
WO2007061254A1 (en) 2005-11-25 2007-05-31 B & C Biopharm. Co., Ltd. Genistein derivatives and anti-fungal composition containing the same
WO2008034016A2 (en) * 2006-09-15 2008-03-20 Foldrx Pharmaceuticals, Inc. Assays for detecting native-state proteins and identifying compounds that modulate the stability of native-state proteins
JP2008094751A (ja) * 2006-10-11 2008-04-24 Ono Pharmaceut Co Ltd プランルカスト水和物含有医薬組成物
KR20110106355A (ko) 2008-12-11 2011-09-28 악센투아 파마슈투칼스 아베 제니스테인의 결정성 형태

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4841077A (en) * 1985-11-18 1989-06-20 Yamanouchi Pharmaceutical Co., Ltd. Isoflavone derivatives, and salts thereof, and cancerocidal and immunosuppressive agents containing the same
WO2002081491A2 (en) * 2001-04-09 2002-10-17 Instytut Farmaceutyczny New genistein derivatives and pharmaceutical preparations containing them

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
染料木黄酮的研究进展;李明等;《西南国防医药》;20080430;第18卷(第4期);617-620 *

Also Published As

Publication number Publication date
JP2017061566A (ja) 2017-03-30
CN104860913B (zh) 2018-05-04
BRPI0923504A2 (pt) 2020-05-26
IL235943A0 (en) 2015-01-29
CN104860913A (zh) 2015-08-26
HK1164698A1 (en) 2012-09-28
KR20170091177A (ko) 2017-08-08
KR20110106355A (ko) 2011-09-28
ZA201105045B (en) 2012-10-31
US20150290166A1 (en) 2015-10-15
IL213473A0 (en) 2011-07-31
EP2373326A1 (en) 2011-10-12
IL213473A (en) 2014-12-31
EP2373326A4 (en) 2012-09-05
KR101849059B1 (ko) 2018-04-13
AU2009324489B2 (en) 2015-11-12
US20120035253A1 (en) 2012-02-09
US9012495B2 (en) 2015-04-21
EP2373326B1 (en) 2016-03-09
CA2746652C (en) 2018-03-06
JP6067781B2 (ja) 2017-01-25
WO2010068861A1 (en) 2010-06-17
JP2015193630A (ja) 2015-11-05
CN102292097A (zh) 2011-12-21
JP5898958B2 (ja) 2016-04-06
AU2009324489A1 (en) 2011-07-28
US9492425B2 (en) 2016-11-15
CA2746652A1 (en) 2010-06-17
JP2012512164A (ja) 2012-05-31

Similar Documents

Publication Publication Date Title
CN104860913B (zh) 染料木黄酮的晶型
CN113698356B (zh) 新型parp抑制剂的稳定晶型及其制备方法
CN108884080B (zh) 激酶抑制剂化合物的多晶型、含其的药物组合物及其制备方法和应用
JP6178799B2 (ja) アプレピタントｌ−プロリン溶媒和化合物−組成物及び共結晶
JP2011144182A (ja) ２，５−ジオン−３−（１−メチル−１ｈ−インドール−３−イル）−４−［１−（ピリジン−２−イルメチル）ピペリジン−４−イル］−１ｈ−インドール−３−イル］−１ｈ−ピロール一塩酸塩の結晶
JP2023512621A (ja) フルバチニブ又はそのメタンスルホン酸塩の結晶形およびその製造方法
CN110291079A (zh) 与吡啶酰基哌啶5-ht1f激动剂相关的组合物和方法
US7863325B2 (en) Crystalline genistein sodium salt dihydrate
EA023238B1 (ru) Замещенные производные индола для лечения иммунологических расстройств
CN114401720A (zh) 多酪氨酸激酶抑制剂的晶型、制备方法及其用途
CN120344512A (zh) 氧异吲哚-5-甲酰胺类化合物或其盐、溶剂合物的结晶形式或无定形形式
WO2022171117A1 (zh) 含氮稠杂环化合物的盐、晶型及其制备方法、药物组合物和用途
HK1164698B (en) Crystalline forms of genistein
CN105085476A (zh) 5-[2,6-二(4-吗啉基)-4-嘧啶基]-4-(三氟甲基)-2-吡啶胺二盐酸盐的晶型及其制备方法
CN104016966A (zh) 3-(4-氨基-1,3-二氢-1-氧代-2h-异吲哚-2-基)-2,6-哌啶二酮新晶型及其制备方法
US20210380586A1 (en) 2-indolyl imidazo[4,5-d]phenanthroline polymorphs and compositions regarding the same
WO2024125591A1 (zh) 苯并恶嗪酮类化合物的结晶及其制备
KR20150079665A (ko) 치환된 인돌 유도체
TW202613102A (zh) Cyp11a1抑制劑的鹽及其晶型、其製備方法和應用
TW202543633A (zh) 喹唑啉酮衍生物的晶型及其製備方法和應用
WO2022199699A1 (zh) 含氮稠杂环化合物的盐的晶型及其制备方法和应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1164698

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1164698

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150527

Termination date: 20191211